Ursolic acid reverses liver fibrosis by inhibiting NOX4/NLRP3 inflammasome pathways and bacterial dysbiosis

Qi Liu (✉ llq6711@163.com)
The First Affiliated Hospital of Nanchang University

Yuan Nie
The First Affiliated Hospital of Nanchang University

Wang Zhang
The First Affiliated Hospital of Nanchang University

Yipeng Wan
The First Affiliated Hospital of Nanchang University

Chenkai Huang
The First Affiliated Hospital of Nanchang University

Xuan Zhu
The First Affiliated Hospital of Nanchang University

Research Article

Keywords: Liver fibrosis, NADPH oxidase 4, NLRP3 inflammasome, Ursolic acid, Intestinal bacteria

Posted Date: May 17th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-516318/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Introduction

Activation of the NOX4/NLRP3 inflammasome pathway has been associated with fibrosis in other organs. An imbalance in intestinal bacteria is an important driving factor of liver fibrosis through the liver-gut axis. This study aimed to explore whether the effect of ursolic acid (UA) on liver fibrosis was associated with the NOX4/NLRP3 inflammasome pathways and intestinal bacteria.

Methods

Wild-type (WT), NLRP3−/−, and NOX4−/− mice and AP-treated mice were injected with CCL4 and treated with or without UA.

Result

UA alleviated liver fibrosis and the expression of NOX4 and NLRP3 was significantly inhibited by UA treatment. Even after CCL4 injection, liver damage and fibrosis-related factors were significantly decreased in NLRP3−/−, NOX4−/−, and AP-treated mice. Importantly, the expression of NLRP3 was obviously inhibited in NOX4−/− and AP-treated mice. In addition, the diversity of intestinal bacteria and the abundance of probiotics in NLRP3−/− and NOX4−/− mice was significantly higher than those in WT mice.

Conclusion

The NOX4/NLRP3 inflammasome pathway plays a crucial role in liver fibrosis and is closely associated with the beneficial effect of UA. The mechanism by which the NOX4/NLRP3 pathway is involved in liver fibrosis may be associated with disordered intestinal bacteria.

Introduction

A key factor of liver fibrosis is the activation of hepatic stellate cells (HSCs), which differentiate into activated myofibroblasts[1]. Uncontrolled chronic damage will lead to liver cirrhosis, which has high morbidity and mortality[2]. Therefore, studying the pathogenesis of liver fibrosis can lay the foundation for future treatments and is essential in delaying the development of liver fibrosis.

NADPH oxidase 4 (NOX4) is the most widely distributed NOX catalytic subunit[3, 4]. NOX4 is abundantly present in hepatocytes and HSCs and can directly or indirectly regulate the cell signaling network through reactive oxygen species (ROS)[3]. NOX4 is the key factor that promotes liver fibrosis via apoptosis and HSC activation. NLRP3 is an intracellular multiprotein complex that is widely involved in cellular immunity and can respond to harmful signals (pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs)), thereby activating caspase1 through autocatalysis, releasing proinflammatory cytokines (such as IL-1β and IL-18), and initiating the repair response[5, 6].
Previous studies showed that NLRP3 inflammasome activation is associated with ovarian[7], kidney[8] and heart[9] fibrosis. However, the role of the NOX4/NLRP3 signaling pathway in liver fibrosis has rarely been studied.

The intestine and liver communicate closely through the biliary tract, portal vein and systemic circulation. A common feature of liver cirrhosis is an increase in potentially pathogenic bacteria and a decrease in beneficial bacteria[10]. The imbalance in intestinal microbes will cause the displacement of microorganisms and their products, lead to an inflammatory cascade and result in liver damage and even liver fibrosis[11]. Once liver cirrhosis worsens, it will lead to intestinal barrier dysfunction and pathological bacterial translocation[12]. The occurrence and progression of liver fibrosis is closely associated with intestinal bacterial disorders. Previous research has shown that the NLRP3 inflammasome can recognize microorganisms and their metabolites, exert intestinal immune functions and thus protect the intestinal tract[13].

Ursolic acid (UA) is a natural compound that is widely found in a variety of plants and has been shown to have antifibrotic effects[14, 15]. UA alleviates liver fibrosis by inhibiting liver inflammation, selectively inducing apoptosis in activated HSCs and inhibiting HSC proliferation[16], but the specific mechanism is still unclear. Since NOX4 and the NLRP3 inflammasome are closely associated with the development and progression of fibrosis in many organs, these factors are also associated with changes in intestinal microbes. We aimed to explore whether the antifibrosis mechanism of UA is associated with the NOX4/NLRP3 signaling pathway and the regulation of intestinal bacteria.

Materials And Methods

Animal Models and Experimental Design

The wild-type (WT) C57BL/6 mice used in this experiment were obtained from the Department of Laboratory Animal Science of Nanchang University, and both NOX4−/− mice and NLRP3−/− mice were purchased from the Jackson Laboratory in the United States. All animals were cared for humanely in accordance with the guidelines of the institution. The animals were kept in an environment with 12 hours of light and 12 hours of darkness, the room temperature was 20-24°C, the humidity was 50%-60%, and food and sterile water were freely available. According to the principle of random allocation, WT mice weighing 20~30 g were divided into three groups (n=10): the control group (injected intraperitoneally with 1 ml/kg olive oil twice per week for 8 weeks), CCL4 group (injected intraperitoneally with 1 ml/kg CCL4 twice per week for 8 weeks) and UA group (injected intraperitoneally with 1 ml/kg CCL4 twice per week for 8 weeks and administered 50 mg/kg/d UA by gavage for the last 4 weeks). NLRP3−/− mice were randomly divided into the NLRP3−/− group (n=10, same treatment as the CCL4 group) and the NLRP3−/−+UA group (n=10, same treatment as the UA group). The mice were randomly divided into 3 groups (n=10): the NOX4−/− group (same treatment as the CCL4 group), the NOX4−/−+UA group (same treatment as the UA group) and the CCL4+AP group (the mice were administered CCL4 for 4 weeks, and CCL4 plus 50
mg/kg/d AP (NOX4 biological inhibitor) was administered for an additional 4 weeks). All experimental procedures were approved by the Animal Care and Use Committee of the First Affiliated Hospital of Nanchang University.

**Serological Analysis and Liver Histopathology**

After 8 weeks, all mice were fasted for 72 hours and anesthetized with ether and blood was collected in a 1.5 ml sterile EP tube. The blood was allowed to stand for 10 minutes and was centrifuged for 10 minutes (4°C, 3000 rpm/min) after clotting. The supernatant was collected and sent to the Laboratory Department of the First Affiliated Hospital of Nanchang University to determine the levels of AST and ALT. The mice were sacrificed by cervical dislocation, and whole liver and mouse fecal specimens (cecal contents) were collected. The liver was divided into two parts: one part was fixed in 4% paraformaldehyde for immunohistochemistry (IHC) and enzyme-linked immunosorbent assay (ELISA), while the other part was stored at -80°C for PCR and protein extraction experiments. The liver samples were embedded in paraffin, sectioned and examined by hematoxylin and eosin (HE) staining, Masson's trichrome staining, Sirius red staining, IHC, and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) analysis.

**Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)**

Fluorescent chemicals were used to detect the total amount of products after each PCR cycle to analyze the relative abundance of the target gene. The primers used for qPCR are shown in Online Supplementary Table S1. The ΔΔCT method was used to calculate the relative gene expression.

**16S RNA Gene Sequencing**

The feces of the sacrificed mice were collected and analyzed by the 16S rRNA sequencing method to assess the composition of intestinal bacteria. Microbial DNA was extracted from intestinal contents using the E.Z.N.A.® soil DNA kit (Omega Biotek, USA) according to the manufacturer’s protocols. The final DNA concentration and purity were determined by a NanoDrop 2000 UV-vis spectrophotometer (Thermo Scientific, Wilmington, USA), and the DNA quality was checked by 1% agarose gel electrophoresis. The V3-V4 hypervariable regions of the bacterial 16S rRNA gene were amplified with the primers 338F (5’-ACTCCTACGGGAGGCAGCAG-3’) and 806R (5’-GGACTACHVGGGTWTCTAAT-3’) by a thermocycler PCR system (GeneAmp 9700, ABI, USA). The library was constructed according to the standard operating procedures of the Illumina MiSeq platform (Illumina, San Diego, USA). Sequencing was performed using the MiSeq PE300 Illumina platform.

**Statistical Analysis**

Quantitative data are expressed as the means ± standard deviation (SD). Normality was assessed using the Kolmogorov-Smirnov test, and normally distributed data were analyzed by one-way analysis of variance (ANOVA). Statistical analyses were performed with IBM SPSS statistics version 26.0. GraphPad Prism 8.0 was used for image production. Values of P<0.05 were considered significant.
Results

UA reverses liver damage and hepatic fibrosis

HE staining, Masson’s trichrome staining and Sirius red staining were used to observe the effect of UA on liver fibrosis. UA treatment significantly reduced the effects of CCL4 on the structure of liver lobules, fibrous septum formation and collagen deposition in mice, with reduced inflammatory cell infiltration (P<0.010) (Figure 1A, 1C-D). To determine the effect of UA on liver function, we evaluated the serum levels of ALT and AST and measured the liver levels of hydroxyproline, which is the main component of collagen tissue (Figure 1B). The levels of ALT, AST and hydroxyproline in the CCL4 group were significantly improved (P<0.050) compared with those in the control group (P<0.050). However, this effect was decreased by UA treatment.

Liver fibrosis is often accompanied by changes in the expression of fibrosis-related factors. IHC showed that the biomarkers of activated HSCs, including α-SMA and Collagen-1\[^{17, 18}\], in the liver tissues of the CCL4 group were significantly higher than those of the control group (P<0.050). The TUNEL assay results showed that hepatocyte apoptosis in the CCL4 group was increased. However, in the UA group, these two effects were significantly reversed (Figure 2A). This result suggested that UA could inhibit HSCs activation and hepatocyte apoptosis. At the mRNA and protein levels, the expression of liver fibrosis-related factors (α-SMA, Collagen-1, and TIMP-1\[^{17}\]) increased in the CCL4 group (P<0.001), while the expression of the antifibrotic factor MMP-1 decreased\[^{19}\] (P<0.010). After UA treatment, the expression of the antifibrotic factor MMP-1 increased (P<0.010) (Figure 2B-D). This result suggests that UA can reverse liver fibrosis.

UA reduces liver fibrosis by inhibiting NOX4 and NLRP3 signaling

To explore the role of the NOX4/NLRP3 pathway in liver fibrosis, we measured the expression of NOX4/NLRP3 in the three groups of mice. The IHC results showed that the expression of NOX4 and NLRP3 was upregulated in mice with CCL4-induced liver fibrosis, and after UA treatment, the expression of NOX4 and NLRP3 was significantly reduced (Figure 3A) (P<0.050). PCR and Western blotting (P<0.050) showed similar results (Figure 3C-E) (P<0.010). This finding demonstrated that the development of liver fibrosis was associated with the expression of these two factors.

Inhibiting NLRP3 expression can effectively alleviate liver fibrosis

To further verify the relationship between NOX4 and NLRP3 in the progression of liver fibrosis, NOX4\(^{-/-}\) and NLRP3\(^{-/-}\) mice were constructed. HE staining, Masson’s trichrome staining and Sirius red staining demonstrated that compared with those of WT mice injected with CCL4, inflammatory cell infiltration was reduced and collagen deposition was alleviated in the NLRP3\(^{-/-}\) group (P<0.001) (Figure 4A-C). In addition, the levels of ALT (P<0.050), AST (P<0.010) and hydroxyproline (P<0.050) in CCL4-induced mice were significantly reduced after inhibiting NLRP3 (Figure 4D). The changes in the expression of liver fibrosis-related indicators were similar (Figure 4E-G), suggesting that NLRP3 is an important profibrotic factor in...
the process of liver fibrosis. Next, we explored whether NLRP3 was the target of the antifibrotic effect of UA. Compared with those in the \textit{NLRP3−/−} group, the changes in inflammatory cell infiltration, collagen deposition and fibrous septum formation in the \textit{NLRP3−/−}+UA group were not obvious. The changes in serum indexes and liver fibrosis-related factors were also not obvious (Figure 4A-G). In \textit{NLRP3−/−}+UA mice, the mRNA and protein expression of NOX4 was decreased compared with that in the CCL4 group (P<0.050) (Figure 4H-J).

\textbf{Inhibiting NOX4 expression can effectively alleviate liver fibrosis}

We confirmed that UA exerts its antifibrotic effect by inhibiting NOX4. Compared with WT mice with liver fibrosis, mice in the \textit{NOX4−/−}+CCL4 and CCL4+AP groups showed less inflammatory cell infiltration and lower collagen deposition (P<0.050) (Figure 5A-C). Similarly, the levels of ALT, AST and hydroxyproline were lower than those in WT mice (Figure 5D), indicating that liver function was significantly restored by inhibiting NOX4. The expression of related fibrotic factors also indicates that NOX4 plays an important role in the development of liver fibrosis (Figure 5E-G). These results showed that inhibiting NOX4 could improve liver fibrosis and that NOX4 was an important profibrotic factor. Next, we assessed whether UA could reverse liver fibrosis by suppressing NOX4-related signals. HE staining, Masson's trichrome staining and Sirius red staining indicated that compared with those of the \textit{NOX4−/−}+CCL4 group and the CCL4+AP group, there were no significant differences in fibrous septum formation, collagen deposition or inflammatory cell infiltration in the \textit{NOX4−/−}+UA group, but the levels were still lower than those in the WT group (P<0.010) (Figure 5A-C). Similarly, the serum indexes after UA treatment also recovered to a certain extent, the expression of profibrotic factors was also downregulated, and the expression of antifibrotic factors was upregulated (Figure 5D-G).

\textbf{NOX4 effectively stimulates NLRP3 expression}

Our results confirmed that NOX4 and the NLRP3 inflammasome are two key molecules by which UA exerts antifibrotic effects. We further analyzed the upstream and downstream relationship between NOX4 and NLRP3. In NLRP3−/−+CCL4 mice, the mRNA and protein expression of NOX4 was not significantly decreased compared with that in WT+CCL4 mice (P>0.050) (Figure 4H-J). Next, we determined the expression of NLRP3 in \textit{NOX4−/−} mice. The mRNA and protein levels of NLRP3 in all \textit{NOX4−/−} mice were significantly lower than those in WT+CCL4 group mice (P<0.010) (Figure 5H-J). These results suggested that NOX4 may be an upstream signal of NLRP3.

\textbf{UA improves the intestines of mice with liver fibrosis by inhibiting the NOX4/NLRP3 signaling pathway}

The intestinal microbiota is an important indicator of intestinal and systemic states. Based on animal models of liver fibrosis, we explored the effect of intestinal bacteria during liver fibrosis and the effect of UA treatment. The intestinal contents of mice were collected to assess the structure of intestinal bacteria by high-throughput sequencing.
First, we examined the α-diversity indicators (Chao1 index, Shannon index) of the four groups to understand gut microbial diversity (Figure 6A-B) (P<0.050). We observed that diversity in the CCL4 group was significantly lower than that in the control group, while diversity in the NOX4/- group and the NLRP3/- group were significantly improved compared with that in the CCL4 group. Next, we conducted β-diversity analysis to further evaluate the differences in intestinal structure between groups (Figure 6C-D). The PCoA plot and NMDS analysis showed differences in the intestinal structure in the control group, CCL4 group, NOX4/- group and NLRP3/- group, and the abundances of microbial species were also different (Figure 6E).

In terms of microbial abundance, the performance of each group was different. At the gate level (Figure 7A-C), the abundance of the beneficial bacterium Firmicutes in the CCL4 group was lower than that in the control group (P<0.001). Firmicutes abundance was significantly increased in the NOX4/- group and NLRP3/- group (P<0.001). In contrast, the harmful bacterium Proteobacteria showed the opposite trend (P<0.050). At the species level (Figure 7D-I), compared with the control group, mice in the CCL4 group carried more harmful Akkermansia bacteria and less beneficial Lactobacillus bacteria in their gut microbiota. Compared with the CCL4 group, the NOX4/- group and the NLRP3/- group had completely opposite trends.

The potential associations of intestinal structure with AST, ALT, and hydroxyproline were determined (Supplementary figure 1A-B). The beneficial bacteria Lactobacillus and the harmful bacteria Akkermansia was associated with liver function indicators (AST, ALT) and hydroxyproline, and the harmful bacteria Akkermansia was positively correlated with these three indicators.

**Discussion**

In this study, we found that UA could alleviate CCL4-induced liver fibrosis, and proposed that the beneficial effect of UA on liver fibrosis may be achieved through the NOX4/NLRP3 signaling pathway and improving intestinal bacteria.

HSCs are the main cell types that cause hepatic cirrhosis[20]. In response to chronic injury, HSCs undergo activation, which is characterized by the loss of lipid droplets and the production of extracellular matrix (ECM) proteins[2, 21]. Activated HSCs and cross-linked ECM lead to liver fibrosis and subsequent liver failure[2, 22]. In the digestive system, liver cirrhosis is the most common nontumoral cause of death[23]. Therefore, exploring the specific mechanism of liver fibrosis is critical for treating chronic liver disease. NOX has seven isoforms (NOX1-NOX5, DUOX1 and DUOX2), and these proteins are the main sources of ROS, while NOX4 plays an important role in the development of fibrosis[24, 25]. NOX4 is the most widely distributed NOX and can directly or indirectly regulate the cell signaling network through ROS. Previous research showed that NOX4 is the key to liver cell apoptosis and HSCs activation in CCL4-induced WT mice[26-28]. We further demonstrated the role of NOX4 in NOX4/- mice with liver fibrosis. Our study showed that NOX4 expression in mice with liver fibrosis was increased, while the degree of fibrosis in
NOX4−/− mice was reduced. This finding indicates that NOX4 is involved in liver fibrosis. The relationship between the NLRP3 inflammasome and fibrosis has been reported in various studies. The NLRP3 inflammasome can be activated by high androgen levels, leading to ovarian interstitial cell fibrosis[7]; NLRP3 inflammasome activation is associated with the development of renal fibrosis in diabetic nephropathy[8]; and NLRP3/IL-1β activation is associated with the formation of cardiac fibrosis[29]. However, the relationship between the NLRP3 inflammasome and liver fibrosis has rarely been reported. In our study, CCL4 was injected into WT mice and NLRP3−/− mice to establish liver fibrosis models, and the results showed that the expression of the NLRP3 inflammasome increased in mice with liver fibrosis. NLRP3−/− mice exhibited decreased inflammatory cell infiltration and reduced liver fibrosis. In addition, the serum indicators of liver function in mice and liver fibrosis-related factors were also decreased. These results indicated that the NLRP3 inflammasome plays an important role in liver fibrosis and that inhibiting NLRP3 inflammasome expression can protect the liver.

Current studies have shown that NOX4 and NLRP3 can induce a variety of diseases have upstream and downstream regulatory relationships. In metabolic diseases, NOX4-dependent fatty acid oxidation promotes the activation of NLRP3 inflammasomes in macrophages and leads to the emergence of diseases, and the NOX4 inhibitor GKT137831 can inhibit the NLRP3 inflammasome[30]. In diabetic rats, the protective effect of acarbose on vascular endothelial function was achieved by inhibiting the NOX4/NLRP3 inflammasome pathway[31]. In acute kidney injury induced by lipopolysaccharide, dexmedetomidine inhibited NLRP3 activation by regulating the TLR4/NOX4/NF-κB pathway, thereby reducing disease development[32]. However, the mutual regulation of NOX4 and NLRP3 in animal models of liver fibrosis is unknown. Therefore, we generated NLRP3−/− and NOX4−/− mice with liver fibrosis. In NLRP3−/− mice, although the expression of NOX4 in the liver was reduced, the difference was not statistically significant, indicating that NLRP3 inhibition does not affect NOX4 expression. However, NLRP3 expression was significantly reduced in NOX4−/− mice. This finding demonstrated that NOX4 may be an upstream signal of NLRP3 in liver fibrosis and can reverse liver fibrosis by inhibiting the NOX4/NLRP3 signaling pathway. However, a study of chronic granulomatosis showed that NLRP3 inflammasome activation does not depend on the ROS produced by NOX[33]. Perhaps there are other signaling molecules that play indirect roles between NOX4 and NLRP3; thus, clarifying the relationship between NOX4 and NLRP3 inflammasomes in the development of liver fibrosis is very important for future treatment of liver diseases.

UA is a natural compound that is widely found in a variety of plants. UA inhibits HSC activation by inhibiting the activity and expression of NOX, thereby reversing liver fibrosis[34]. Our experiments confirmed that UA could reduce neutrophil infiltration by inhibiting NOX4 and reduce collagen deposition and fibrous spacing in mice. In NLRP3−/− mice, we showed for the first time that UA could reverse liver fibrosis by inhibiting the expression of the NLRP3 inflammasome. Our study demonstrated that UA exerted its unique effect on fibrosis by inhibiting the NOX4/NLRP3 signaling pathway in vivo.
The connection between the intestine and the liver is achieved through the gut-liver axis. Changes in intestinal microbes, which account for the majority of bacteria, cause destruction of the intestinal barrier, which can damage liver cells and result in reversible liver fibrosis\(^\text{[35]}\). Studies have shown that rats or patients with liver cirrhosis exhibit pathological bacterial translocation and inflammatory reactions, and the disease progresses rapidly\(^\text{[36]}\). It has also been reported that in patients with liver cirrhosis, the abundance of *Bacteroides* and *Firmicutes* is decreased, while the abundance of *Streptococcus*, *Veillonella* and *Enterobacteriaceae* (including *E. coli*, *Klebsiella*, *Proteus* and *Enterobacter*) is increased\(^\text{[37–39]}\). After treatment with metronidazole combined with ciprofloxacin or neomycin, ampicillin, and vancomycin combined with metronidazole, the disease process was significantly slowed\(^\text{[36]}\). An in vitro study showed that the broad-spectrum antibiotic rifaximin exerts its pharmacological effects by changing the function of *E. coli*\(^\text{[40]}\). Increasing evidence shows that the progression of liver fibrosis is closely associated with disturbances in the intestinal flora.

Our study showed that the intestinal microbiota changed during liver fibrosis, and this change was closely associated with UA-mediated inhibition of the NOX4/NLRP3 signaling pathway. At the phylum level, the abundance of the beneficial bacteria *Firmicutes* in mice with hepatic fibrosis was lower than that in the control group, and the microbial diversity was reduced. After knocking out NOX4 or the NLRP3 inflammasome, the bacterial diversity and abundance increased significantly. In contrast, the harmful bacteria *Proteobacteria* showed the opposite trend. At the species level, the harmful bacterium *Akkermansia* was more abundant in the intestinal microbiota of WT + CCL4 mice than in mice in the other groups, and the beneficial bacterium *Lactobacillus* was lower. This intestinal biological disorder was partially improved after key genes were knocked out. Our research confirmed that the body can affect the intestinal microbiota through the NOX4/NLRP3 signaling pathway, and the abundance of intestinal flora correlates with liver function. There is a positive correlation between beneficial bacteria and liver function. Previous studies have reported the antibacterial effect of UA, but the mechanism by which UA improves intestinal microbes is not clear. Our study showed that UA improved the intestinal flora by inhibiting the NOX4/NLRP3 signaling pathway, thereby restoring liver function and slowing the occurrence and development of liver fibrosis. To further verify our results, we will evaluate the efficacy of UA at the clinical level. In short, the elaboration of this signaling pathway is helpful for both the diagnosis of chronic liver disease and the treatment of hepatic cirrhosis. There are also some limitations to the present study, such as the lack of results regarding the coculture of HSCs in vitro, and additional results regarding ROS intervention.

In summary, this study showed that the NOX4/NLRP3 signaling pathway is essential in the development of liver fibrosis and an important target for the regulation of intestinal flora. UA exerts an antifibrotic effect through this signaling pathway, and NOX4/NLRP3 constitutes a key antifibrotic target in the treatment of chronic liver disease.

**Declarations**
Financial support: This study was supported by the National Natural Science Foundation of China (grant number: 81960120), “Gan-Po Talent 555” Project of Jiangxi Province (GCZ (2012)-1) and the Postgraduate Innovation Special Foundation of Jiangxi Province (YC2020-B046).

Acknowledgments: We would like to thank the National Natural Science Foundation of China for the economic support.

Credit author statement
QL and YN contributed equally to this study. QL designed and wrote the manuscript; YN experimental operation; WZ and YPW analyzed data. XZ and CKH critically revised the manuscript. All of the authors reviewed the manuscript and approved the final version.

Declaration of Competing Interest: The authors declare that there are no conflicts of interest.

Ethics statement: The animal study was reviewed and approved by Institutional Animal Care and Use Committee of the First Affiliated Hospital of Nanchang University (Nanchang, China) (No.20150109).

Data availability statement: All datasets generated for this study are included in the article/Supplementary Material.

References


[27] LAN T, KISSELEVA T, BRENNER D A. Deficiency of NOX1 or NOX4 Prevents Liver Inflammation and Fibrosis in Mice through Inhibition of Hepatic Stellate Cell Activation [J]. PloS one, 2015, 10(7): e0129743.


Figures
Figure 1

UA ameliorates liver damage and hepatic fibrosis in mice with CCl4-induced liver fibrosis. (A): HE staining, Masson's trichrome staining and Sirius red staining (200× magnification); (B): The levels of ALT, AST and hydroxyproline were measured by ELISA; (C): The degree of fibrosis was assessed by fibrosis scoring and the positive area (%). The data are presented as the means±SD in each group. *P<0.050, **P<0.010 and ***P<0.001.
UA exerts antifibrotic effects by impacting the expression of fibrosis-related factors (A): IHC was used to measure the levels of α-SMA and Collagen-1. Hepatocyte apoptosis was assessed by TUNEL assays; (B): The expression of α-SMA, Collagen-1, TIMP-1 and MMP-1 was determined by qRT-PCR; (C-D): The levels of Collagen-1, TIMP-1 and MMP-1 were determined by Western blotting. The data are presented as the means±SD in each group. *P<0.050, **P<0.010 and ***P<0.001.
Figure 3

UA reduces CCL4-induced liver fibrosis by inhibiting NOX4 and NLRP3 signaling. (A): IHC was used to examine the effect of UA on NOX4 (100×); (B): IHC was used to examine the effect of UA on NLRP3 (100×); (C): The relative mRNA expression of NOX4 and NLRP3 was measured by qRT-PCR. The data are presented as the means±SD in each group. *P<0.050, **P<0.010 and ***P<0.001.
Figure 4

The effect of UA on the expression of NLRP3 inflammasomes in NLRP3-/- mice. (A): HE staining, Masson's trichrome staining and Sirius red staining (200× magnification); (B-C): The degree of fibrosis was assessed by fibrosis scoring and the positive area (%); (D): The levels of ALT, AST and hydroxyproline were measured by ELISA; (E-F): The expression of Collagen-1, α-SMA and TIMP-1 was measured by Western blotting; (G): The expression of α-SMA, Collagen-1, TIMP-1 and MMP-1 was measured by qRT-PCR; (H-I): The protein levels of NOX4 and NLRP3 in NLRP3-/- mice with liver fibrosis were measured by Western blotting; (J): The mRNA levels of NOX4 and NLRP3 in NLRP3-/- mice with liver fibrosis were measured by qRT-PCR. The data are presented as the means±SD in each group. *P<0.050, **P<0.010 and ***P<0.001.
**Figure 5**

The effect of UA on the expression of NLRP3 in NOX4/-/- mice. (A): HE staining, Masson's trichrome staining and Sirius red staining (200× magnification); (B-C): The degree of fibrosis was measured by fibrosis scoring and the positive area (%); (D): The levels of ALT, AST and hydroxyproline were measured by ELISA; (E-F): The expression of Collagen-1, TIMP-1 and α-SMA was measured by Western blotting; (G): The expression of α-SMA, Collagen-1, TIMP-1 and MMP-1 was measured by qRT-PCR; (H-I): Liver protein levels of NOX4 and NLRP3 in NOX4/-/- mice with liver fibrosis were measured by Western blotting; (J): The mRNA levels of NOX4 and NLRP3 in NLRP3/-/- mice with liver fibrosis were measured by qRT-PCR. The data are presented as the means±SD in each group. *P<0.050, **P<0.010 and ***P<0.001.
Figure 6

Changes in gut microbial diversity in the four groups of mice with liver fibrosis. (A-B): Gut microbial diversity is shown by the α-diversity-related indicators Chao1 index and Shannon index in the four groups; (C-D): Microbial community structure between the four groups was determined by β-diversity analysis; (E): The diversity of gut bacteria at the genus level in the four groups. The data are presented as the means±SD in each group. *P<0.050, **P<0.010 and ***P<0.001.
Figure 7

Microbial abundance in each group of mice with CCL4-induced liver fibrosis (A-C): Composition of the intestinal microbiota in each group at the phylum level; (D-F): At the species level, different levels of microbial abundance in each group; (G-I): Different gut microbial abundances in the four groups are shown by the linear discriminant analysis (LDA) score (log10). The data are presented as the means±SD in each group. *P<0.050, **P<0.010 and ***P<0.001.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryFig1.png
- Supplementarytable1.docx